Copegus Articles
Japan recalculates eight drug ingredients due to high sales
27 February 2006
New indications in Japan for S-P drugs
9 January 2006
Stock Commentary - New York week to Dec 5
12 December 2005
Teva, Three RIvers and Par get final OK for generic ribavarin
12 December 2005
Vertex initiates Ph II trial of VX-950 in hep C
12 December 2005
Valeant to buy Infergen from InterMune
5 December 2005
Viragen's Multiferon promising in H5N1 trial
5 December 2005
Roche and Chugai hep C drug under priority review
19 September 2005
Peregrine initiates Ph I study of Tarvacin vs HCV
15 August 2005
AVI BioPharma submits IND for HCV drug
11 July 2005
PegIntron/ribavirin 12-week therapy effective
4 July 2005
Roche's anti-HCV combo performs well in Japan
27 June 2005
Valeant sales rise 22%
16 May 2005
Clarification:
28 April 2005
Valeant's HCV drug gives good Phase II performance
26 April 2005
PegIntron/Rebetol in HCV: positive data
25 April 2005
Schering-Plough back in profit for 1st-qtr
22 April 2005
Pegasys treatment of choice says manufacturer
14 March 2005
EC clears Pegasys for hep C + HIV co-infection
7 February 2005
Idenix extends hep C trial on promising data
17 January 2005
Roche's Pegasys on track for new use in EU
10 January 2005
S-P's Peg-Intron launched in Japan
20 December 2004
Roche's Pegasys gets expanded label in EU
22 November 2004
Schering-Plough's Peg-Intron OKed in Japan
1 November 2004
Priority review for Roche's Pegasys sBLA
11 October 2004
Roche files for new use of Pegasys
13 September 2004
UPDATE: Valeant sees net loss climb 177% for 2nd-qtr
16 August 2004
Valeant sees net loss climb 177% for 2nd-qtr
16 August 2004
Par sees 2nd-qtr 2004 sales rocket 83%
9 August 2004
Roche's net income doubles for 1st-half
26 July 2004
Roche's Pegasys filed for hepatitis B
26 July 2004
Roche 1st-qtr beats expectations
26 April 2004
Pharmaceutical Resources to buy Kali
19 April 2004
Sandoz launches generic Rebetol
12 April 2004
Valeant sees 4th-qtr 2003 revenues slide
15 March 2004
Genotype can determine duration of Hep C therapy
8 March 2004
Promising new data for SciClone's Zadaxin
1 March 2004
Roche beats forecasts with sales up 19%
9 February 2004
S-P launches Rebetol oral solution in USA
26 January 2004
Stock Commentary - New York
22 December 2003
Stock Commentary - New York
17 November 2003
ICN to start Ph III studies for Viramidine
17 November 2003
Roche's Pegasys gains Japanese approval
27 October 2003
Roche beats forecasts with pharma sales up 13% in first 9 months
27 October 2003
S-P to compare hep C therapies
6 October 2003
Stock Commentary - New York
8 September 2003
Rebetol gets FDA OK for use in children
11 August 2003
Roche posts sharp fall in 1st-half profit
28 July 2003
EC changes label for Roche's Pegasys
28 July 2003
ICN sells biomedicals units to former chief
7 July 2003
ICN set to reacquire Ribapharm stake
9 June 2003
Fast growth forecast for hep C drug market
19 May 2003
S-P's new CEO sets out turnaround plan
19 May 2003
ICN Pharma 1st-qtr revenues fall 14%
12 May 2003
Stock Commentary - New York
14 April 2003
Teva and Novartis strike deal with S-P
31 March 2003
ICN Pharma posts 4th-qtr EPS loss of $1.20
17 March 2003
Schering-Plough gives $0.75-$0.85 EPS guide
17 March 2003
Stock Commentary - Week to Feb 10 - New York
17 February 2003
Roche undercuts rival with ribavirin brand
20 January 2003
ICN agreement with Roche on ribavirin
13 January 2003
ICN turns up heat on Ribapharm board
6 January 2003
Ribapharm sues Roche for patent infringement
12 August 2002
FDA grants Pegasys fast-track review
22 July 2002
Ribapharm confident on 2nd-qtr results
15 July 2002
Roche gets OKs for Pegasys, Copegus
1 July 2002
Roche's Pegasys: "unprecedented efficacy in hep C"
29 April 2002
ICN's Ribapharm goes public
22 April 2002
ICN Pharma unit Ribapharm files S-1 amendment
1 April 2002
ICN defending ribavirin patent
11 March 2002
Record revenues reported at ICN
4 March 2002
Enzon starts Phase II study in lung cancer
18 February 2002
ICN Pharma files Ribapharm IPO amendment
18 February 2002
ICN earnings to exceed expectations.
21 January 2002
S-P's PEG-Intron demand difficulties.
21 January 2002
Maxim initiates Ceplene Phase II trials
7 January 2002
Maxim initiates Ceplene Phase II trials
19 December 2001
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
